

SKIN ELEMENTS LIMITED

ABN 90 608 047 794

and its controlled entities



Appendix 4E

Preliminary Final Report

2025

Corporate directory

Current Directors

Peter Malone	<i>Executive Chairman</i>
Filippo (Phil) Giglia	<i>Non-Executive Director</i>
Stuart Usher	<i>Non-Executive Director</i>

Company Secretary

Stuart Usher

Registered Office

Street: 1255A Hay Street
West Perth WA 6005

Postal: 1255A Hay Street
WEST PERTH WA 6005

Telephone: +61 (0)8 6311 1900

Facsimile: +61 (0)8 6311 1999

Email: info@skinelements.com

Website: www.skinelementslimited.com

Auditors

BDO Audit Pty Ltd

Street: Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000

Telephone: +61 (0)8 6382 4600

Facsimile: +61 (0)8 6382 4601

Website: www.bdo.com.au

Share Registry

MUFG Corporate Markets (AU)

Street: Level 12, QV1 Building, 250 St Georges Terrace
Perth WA 6000

Telephone: 1300 554 474 (within Australia)
+61 1300 554 474 (International)

Facsimile: +61 (0)8 6370 4203

Email: support@cm.mpms.mufg.com

Website: au.investorcentre.mpms.mufg.com

Securities Exchange

Australian Securities Exchange

Street: Level 40, Central Park, 152-158 St Georges Terrace
Perth WA 6000

Telephone: 131 ASX (131 279) (within Australia)

Telephone: +61 (0)2 9338 0000

Facsimile: +61 (0)2 9227 0885

Website: www.asx.com.au

ASX Code: SKN

Contents

 Company update1

 Consolidated statement of profit or loss and other comprehensive income6

 Consolidated statement of financial position7

 Consolidated statement of changes in equity8

 Consolidated statement of cash flows9

 Notes to the preliminary final report10



Company update

1. Operating and financial review

1.1. Nature of Operations and Principal Activities

Skin Elements is a researcher and developer of the innovative proprietary SE Formula™ biotechnology. This Green Tech plant-based and organic sourced SE Formula™ is used in the Company's proprietary flagship products including the SuprCuvr TGA-registered hospital-grade plant-based disinfectant, ECO-Nurture plant bio-stimulant, Invisi Shield alcohol free natural sanitiser, Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare and Elizabeth Jane Natural Cosmetics brand.

1.2. Operations Review

1.2.1. Development of SE Formula™

The SE Formula™ has been developed by Skin Elements over the last 15 years and is the core of every natural product developed by Skin Elements. Products with the SE Formula™ have scientifically proven as high performance while using only natural and plant-based ingredients.

Skin Elements has a three-phase development process leading into commercial scale production and sales:

-  **Phase 1** Pure research and development to undertake investigations into natural organic ingredients and processes to prepare prototype formulations.
-  **Phase 2** Produce test batches and undertake product trials, test marketing and regulatory certifications.
-  **Phase 3** Negotiate distribution agreements and commence scale up production and launch into commercialisation.

1.2.2. Eco Nurture Plant Bio-Stimulant Phase 3 Commencing

ECO-Nurture is a sustainable, horticultural-specific plant bio stimulant product developed from the plant-based SE Formula biotechnology research and development program as an effective alternative to chemical-based agricultural sprays currently used in crop disease protection globally.

During the year, Skin Elements has continued to work through the certification for wide spread adoption of ECO-Nurture for the New Zealand kiwifruit industry under Zespri's spray list approved Zespri Crop Protection Standards. Headquartered in New Zealand, Zespri is the world's largest marketer of kiwifruit with over \$5 billion in sales annually.

Assessment of ECO-Nurture on over 120 kiwifruit orchards in New Zealand over the past three growing seasons has delivered positive outcomes on kiwifruit plant protection and productivity without any chemical residue. ECO Nurture has demonstrated that it is effective against bacteria which has negatively impacted kiwifruit industry in addition to supporting high fruit quality, yield quantity, and cosmetic look of the fruit with zero residual toxicity.

During the year, over 2,400 litres of ECO Nurture concentrate have been delivered to kiwi fruit orchard managers in New Zealand with a further 800 litres delivered in August.

Skin Elements has now commenced the commercial roll-out of ECO-Nurture for the 2026 New Zealand kiwifruit growing season with further deliveries to follow.

1.2.3. SuprCuvr disinfectant Phase 3 Commencing

SuprCuvr is a TGA registered hospital-grade disinfectant made from the Company's proprietary 100% plant-based SE formula. It combines the world's highest level of efficacy against viral and bacterial infection with a 100% plant-based organic input certified formula to present a significant market opportunity for a chemical-free disinfectant in large-scale settings such as food manufacturing, hospitality retailing businesses, public transport, and health services.

SuprCuvr is currently being used by Spotless cleaning contractors in the Melbourne city trains with a further 900 litres delivered in August 2025. SuprCuvr is also undergoing trials with the agriculture sector in New Zealand. SuprCuvr is TGA registered in Australia and has MPI registration in New Zealand.

1.2.4. Soleo Organics Phase 3 Commercialisation Negotiations

Soléo Organics is an award-winning, natural and organic sunscreen formulation, providing a highly effective, high-performance chemical-free sunscreen range. It was the first application borne out of Skin Elements' SE Formula research and development program.

Soléo Organics is globally recognised, with certification by the TGA in Australia, FDA in the United States, Health Canada, European Union and the United Kingdom, and Ministry of Health, Japan.

Skin Elements is working on the development of a new, premium SPF50 Soléo Organics sunscreen for the domestic market, as well as negotiations with leading health retail group in the United Kingdom for distribution of the Soléo Organics sunscreen formulation under white label.

Company update

1.2.5. PapayaActivs Phase 2 Completion

Skin Elements continued to progress Phase 2 improvements in the PapayaActivs formulation and expansion of the product range. The Company also undertook small scale Phase 3 test market of skincare ranges through its online store.

PapayaActivs combines a high concentration of natural pawpaw extract with other active natural ingredients to help relieve the symptoms of skin conditions, like psoriasis, rashes, eczema, assist in healing of minor burns and wounds, and relieve mild muscle, joint and arthritic pain. PapayaActivs is listed on the TGA Australian Register of Therapeutic Goods.

1.2.6. Research and development (R&D) tax incentive grant income

During the year, Skin Elements received R&D Rebate of \$1.19 million in relation to the eligible research and development spend in the 2024 financial year.

The Company's commitment to the continued research and development of its natural SE Formula Biotechnology sees it eligible for the Federal Government's R&D tax incentive for the FY2025 with R&D Rebate calculation of \$635k as at 30 June 2025.

During the year, Skin Elements received an advance of \$433k under a R&D Rebate advance facility provided by Radium Capital in relation to the FY2025 eligible R&D expenditure.

1.2.7. Rights Issue

During the period, the Company completed a non-renounceable rights issue to existing shareholders on the basis of 1 new share for 5 existing shares. The entitlement issue was successfully completed with entitlement and shortfall applications received for the full 171,230,552 shares (and attaching 171,230,552 free options exercisable at \$0.01 on or before 7 March 2028) raising \$513,692 in cash.

The Company also received additional oversubscription applications for 47,830,803 shares (with 47,830,803 attaching free options exercisable at \$0.01 on or before 7 March 2028) for an additional \$143,492 cash and these were issued accordingly as a placement under the Company's LR7.1 capacity.

1.2.8. Repayment of Borrowings

As approved by Shareholders at the 2024 Annual General Meeting, the Company issued 166,666,667 equity securities to Directors and Key Management for \$500,000 unpaid executive services and Directors' services in accordance with service agreements.

1.2.9. Performance Rights

At the Company's 2024 Annual General Meeting, shareholder approval was obtained to issue 100,000,000 Class A performance rights, and 62,000,000 Class B performance rights, that will convert into shares pursuant to the Equity Incentive Plan (2024).

These performance rights were issued to Peter Malone, Executive Chairman, Non-Executive Directors Filippo (Phil) Giglia and Stuart Usher, and key management Craig Piercy and Leo Fung and have been valued in accordance with accounting standards and issued.

The Class A performance rights were deemed to have vested immediately and converted to 100,000,000 fully paid ordinary shares in December 2024.

1.3. Financial Review

1.3.1. Key profit and loss measures

	Movement (increased/ decreased)	Movement \$	2025 \$	2024 \$
 Revenues from ordinary activities	increased	53,755	469,957	416,202
 Loss from ordinary activities after tax	decreased	432,822	(1,728,461)	(2,161,283)
 EBITDA Loss	decreased	(192,615)	(1,629,788)	(1,822,403)

1.3.2. Key net asset measures

	Movement (increased/ decreased)	Movement \$	2025 \$	2024 \$
 Cash and cash equivalents	decreased	55,423	59,648	115,071
 Working capital deficit (excluding prepayments)	increased	274,545	(1,944,428)	1,669,883
 Net tangible liabilities	increased	304,223	(1,937,061)	(1,632,838)
 Net liabilities	increased	304,223	(1,937,061)	(1,632,838)

Company update

1.4. Future Developments, Prospects, and Business Strategies

Likely developments in the operations, business strategies and prospects of the Group include:

-  The Company will undertake future capital raising through either equity placement facility, private placement or entitlement issue, and the consideration of other equity and debt proposals
-  The Company will continue to focus on development and commercialisation of its natural anti-microbial technology as set out in its review of operations.

Other likely developments, future prospects and business strategies of the operations of the Group and the expected results of those operations have not been included in this report particularly given the early stage of the Company's commercial operations with its new expanded range of natural and organic products. The Directors believe that the inclusion of such information would be likely to be unreasonably prejudicial to the Group.

1.5. Environmental Regulations

The Group's operations are not subject to significant environmental regulations in the jurisdictions it operates in, namely Australia.

The Directors have considered the enacted *National Greenhouse and Energy Reporting Act 2007* (the NGER Act) which introduced a single national reporting framework for the reporting and dissemination of information about the greenhouse gas emissions, greenhouse gas projects, and energy use and production of corporations. At the current stage of development, the Directors have determined that the NGER Act has no effect on the Company for the current, nor subsequent, financial year. The Directors will reassess this position as and when the need arises.



PETER MALONE

Executive Chairman

Dated this Friday, 29 August 2025



Results for announcement to the Market

for the year ended 30 June 2025

1. Reporting period (item 1)				
Report for the financial year ended:		30 June 2025		
Previous corresponding period is the year months ended:		30 June 2024		
2. Results for announcement to the market		Movement	Percentage %	Amount \$
Increase in revenues from ordinary activities (item 2.1)		↑	12.92 to	469,957
Increase in loss from ordinary activities after tax attributable to members (item 2.2)		↑	(20.03) to	(1,728,461)
Increase in loss after tax attributable to members (item 2.3)		↑	(20.03) to	(1,728,461)
2.1. Dividends (item 2.4)			Amount per Security \$	Franked amount per security %
Interim dividend			nil	n/a
Final dividend			nil	n/a
Record date for determining entitlements to the dividend (item 2.5)		n/a		
2.2. Brief explanation of any of the figures reported above necessary to enable the figures to be understood (item 2.6): Refer to Company update on page 1 of this report.				
3. Preliminary Final Report				
3.1. Statement of comprehensive income (item 3): Refer to Consolidated statement of profit or loss and other comprehensive income on page 6				
3.2. Statement of financial position (item 4): Refer to Consolidated statement of financial position on page 7				
3.3. Statement of cash flows (item 5): Refer to Consolidated statement of cash flows on page 9				
3.4. Statement of changes in equity (item 6): Refer to Consolidated statement of changes in equity on page 8				
4. Dividends (item 7) and Returns to shareholders including distributions and buy backs (item 14.2) Nil.				
4.1. Details of dividend or distribution reinvestment plans in operation are described below (item 8): Not applicable				
5. Ratios			Current Period \$	Previous corresponding Period \$
5.1. Financial Information relating to 5.2 and 5.3:				
Earnings for the period attributable to owners of the parent			(1,728,461)	(2,161,283)
Net assets			(1,937,061)	(1,632,838)
Less: Intangible assets (including net deferred tax balances)			-	-
Net tangible assets			(1,937,061)	(1,632,838)

Results for announcement to the Market

for the year ended 30 June 2025

5	Ratios (cont.)		Current Period No.	Previous corresponding Period No.
	Fully paid ordinary shares		1,049,714,117	563,986,095
	Weighted average number of ordinary shares outstanding during the period used in calculation of basic EPS		557,264,784	557,264,784
			¢	¢
5.2.	Net tangible assets backing per share (item 9):		(0.185)	(0.290)
5.3.	Earnings per share attributable to owners of the parent (item 14.1):		(0.310)	(0.388)
As at 30 June 2025 the Group has 410,412,553 unissued shares under options (2024: 191,351,198) and 62,000,000 performance shares on issue (2024: 62,000,000). The Group does not report diluted earnings per share on losses generated by the Group. During the year, the Group's unissued shares under option and performance shares were anti-dilutive.				
6.	Details of entities over which control has been gained or lost during the period (item 10):			
6.1.	Control gained over entities			
	 Name of entities (item 10.1)	Nil		
	 Date(s) of gain of control (item 10.2)			
6.2.	Loss of control of entities			
	 Name of entities (item 10.1)	Nil		
	 Date(s) of loss of control (item 10.2)	N/A		
6.3.	Contribution to consolidated profit (loss) from ordinary activities after tax by the controlled entities to the date(s) in the current period when control was gained / lost (item 10.3).	Nil		
6.4.	Profit (loss) from ordinary activities after tax of the controlled entities for the whole of the previous corresponding period (item 10.3)	Nil		
7.	Details of associates and joint venture (item 11):			
	 Name of entities (item 11.1)	Nil		
	 Percentage holding in each of these entities (item 11.2)	n/a		
			Current Period \$	Previous corresponding Period \$
	 Aggregate share of profits (losses) of these entities (item 11.3)		N/A	N/A
8.	Any other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position (item 12): Refer to Company update on page 1 of this report.			
9.	The financial information provided in the Appendix 4E is based on the preliminary final report (attached), which has been prepared in accordance with Australian Accounting Standards (item 13).			
10.	Commentary on the results for the period (item 14): Refer to Company update on page 1.			
11.	The preliminary final report has been prepared based on the 30 June 2025 accounts which are in the process of being audited by an independent Audit Firm in accordance with the requirements of s.302 of the <i>Corporations Act 2001</i> (Cth). (item 15)			

Consolidated statement of profit or loss and other comprehensive income

for the year ended 30 June 2025

	Note	2025 \$	2024 \$
<i>Continuing operations</i>			
Revenue	1.1	469,957	416,202
Cost of sales		(63,665)	(54,328)
Gross profit		406,292	361,874
Other income	1.2	637,849	1,197,149
Administrative and other costs		(1,441,541)	(822,228)
Research and development costs		(1,190,906)	(2,487,755)
Selling and distribution costs		(45,319)	(74,017)
Operating loss		(1,633,625)	(1,824,977)
Interest and finance costs		(94,836)	(81,851)
Impairment expense		-	(254,455)
Loss before tax	2.1	(1,728,461)	(2,161,283)
Income tax benefit		-	-
Net loss for the year		(1,728,461)	(2,161,283)
<i>Other comprehensive income, net of income tax</i>		-	-
Other comprehensive income for the period, net of tax		-	-
Total comprehensive income attributable to members of the parent entity		(1,728,461)	(2,161,283)
<i>Earnings per share:</i>		¢	¢
Basic and diluted loss per share (cents per share)	6.4	(0.31)	(0.39)

The consolidated statement of profit or loss and other comprehensive income is to be read in conjunction with the accompanying notes.

Consolidated statement of financial position

as at 30 June 2025

Current assets

Cash and cash equivalents

Trade and other receivables

Inventories

Other current assets

Total current assets*Non-current assets*

Right-of-use asset - property, plant, and equipment

Intangible assets

Total non-current assets**Total assets***Current liabilities*

Trade and other payables

Borrowings

Total current liabilities**Total liabilities****Net assets***Equity*

Issued capital

Reserves

Accumulated losses

Total equity

Note	2025 \$	2024 \$
3.1	59,648	115,071
3.2	653,197	1,258,884
4.1	-	31,908
3.3.1	5,096	28,680
	717,941	1,434,543
	2,271	8,365
4.2	-	-
	2,271	8,365
	720,212	1,442,908
3.4.1	2,212,883	2,344,019
3.5.1	444,390	731,727
	2,657,273	3,075,746
	2,657,273	3,075,746
	(1,937,061)	(1,632,838)
5.1.1	25,868,692	24,444,454
5.4	335,827	335,827
	(28,141,580)	(26,413,119)
	(1,937,061)	(1,632,838)

The consolidated statement of financial position is to be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity

for the year ended 30 June 2025

	Note	Contributed equity \$	Accumulated losses \$	Share-based payment reserve \$	Total equity \$
<i>Balance at 1 July 2023</i>		24,244,454	(24,464,349)	824,698	604,803
Loss for the year attributable to the owners of the parent		-	(2,161,283)	-	(2,161,283)
Other comprehensive income for the year attributable to the owners of the parent		-	-	-	-
Total comprehensive income for the year attributable to the owners of the parent		-	(2,161,283)	-	(2,161,283)
<i>Transaction with owners, directly in equity</i>					
Shares issued during the year (<i>net of costs</i>)	5.1.1	200,000	-	-	200,000
Share-based payments during the year: <i>rights</i>	5.3.1	-	-	(276,358)	(276,358)
Transfers to/(from) reserves	5.3.1		212,513	(212,513)	-
Balance at 30 June 2024		24,444,454	(26,413,119)	335,827	(1,632,838)
<i>Balance at 1 July 2024</i>		24,444,454	(26,413,119)	335,827	(1,632,838)
Loss for the year attributable to the owners of the parent		-	(1,728,461)	-	(1,728,461)
Other comprehensive loss for the year attributable to the owners of the parent		-	-	-	-
Total comprehensive loss for the year attributable to the owners of the parent		-	(1,728,461)	-	(1,728,461)
<i>Transaction with owners, directly in equity</i>					
Shares issued during the half-year (<i>net of costs</i>)	5.1.1	1,044,238	-	-	1,044,238
Share-based payments during the half-year: <i>rights</i>	5.3.1	-	-	380,000	380,000
Conversion of Class A performance rights	5.1.1	380,000	-	(380,000)	-
Balance at 30 June 2025		25,868,692	(28,141,580)	335,827	(1,937,061)

The consolidated statement of changes in equity is to be read in conjunction with the accompanying notes.

Consolidated statement of cash flows

for the year ended 30 June 2025

Cash flows from operating activities

Receipts from customers	484,391	403,821
Payments to suppliers and employees	(1,351,595)	(1,734,801)
Receipt of <i>Research and development tax incentive</i> grant income	1,193,606	1,129,934
Interest paid and facility fees	(94,836)	(81,851)
Interest received	2,280	3,520

Net cash used in operating activities*Cash flows from investing activities***Net cash used in investing activities***Cash flows from financing activities*

Proceeds from issue of shares	5.1.1	657,187	200,000
Share issue costs		(109,119)	(39,708)
Proceeds from borrowings		523,166	983,413
Repayments of borrowings		(1,360,503)	(1,107,689)

Net cash provided by financing activities**Net decrease in cash and cash equivalents held**

Cash and cash equivalents at the beginning of the year

Cash and cash equivalents at the end of the year

Note	2025 \$	2024 \$
	484,391	403,821
	(1,351,595)	(1,734,801)
	1,193,606	1,129,934
	(94,836)	(81,851)
	2,280	3,520
	233,846	(279,377)
	-	-
5.1.1	657,187	200,000
	(109,119)	(39,708)
	523,166	983,413
	(1,360,503)	(1,107,689)
	(289,269)	36,016
	(55,423)	(243,361)
	115,071	358,432
3.1	59,648	115,071

The consolidated statement of cash flows is to be read in conjunction with the accompanying notes.

Notes to the preliminary final report

for the year ended 30 June 2025

Note	1	Revenue and other income		2025 \$	2024 \$
1.1		Revenue			
		Sales to customers		469,957	416,202
				469,957	416,202
1.2		Other Income			
		Research and development tax incentive grant income		635,592	1,193,629
		Other income		2,257	3,520
				637,849	1,197,149

Note	2	Expenses	Note	2025 \$	2024 \$
2.1		Expenses by nature			
		 Administration expenses	2.2	420,391	414,222
		 Advertising and marketing expenses		45,319	74,017
		 Amortisation	4.2	6,094	6,094
		 Corporate expenses	2.3	205,391	181,354
		 Employee benefits expense	2.4	798,973	187,415
		 Impairment expense		-	254,455
		 Occupancy costs		105,528	114,994
		 Manufacturing, purchasing, and distribution costs		63,665	54,328
		 Research and development expenses		1,190,906	2,487,755
		Total expenses by nature		2,836,267	3,774,634
2.1.1		Reconciliation to net profit or loss before tax			
		Total revenue and other income		1,107,806	1,613,351
		Less: Total expenses by nature		(2,836,267)	(3,774,634)
		Net loss before tax		(1,728,461)	(2,161,283)
2.2		Administration expenses			
		 Accounting expenses		82,541	121,143
		 External consulting fees		37,585	30,000
		 Interest expenses and finance facility costs		94,836	81,851
		 Other expenses		205,429	181,228
				420,391	414,222
2.3		Corporate expenses			
		 ASX fees		31,924	37,705
		 Audit expenses		87,945	88,362
		 Legal expenses		61,690	32,040
		 Share Registry and shareholder communications		23,832	23,247
				205,391	181,354

Notes to the preliminary final report

for the year ended 30 June 2025

Note	2	Expenses (cont.)	2025 \$	2024 \$	
2.4		Employee benefits expense			
		 Directors' fees	140,000	160,000	
		 Executive services contracts	239,782	239,782	
		 Wages and salaries – non-R&D	39,191	63,991	
		 Share-based performance rights: <i>amortisation</i>	380,000	(276,358)	
			798,973	187,415	
Note	3	Financial assets and financial liabilities			
3.1		Cash and cash equivalents	2025 \$	2024 \$	
		Cash at bank	59,648	115,071	
			59,648	115,071	
3.2		Trade and other receivables	Note	2025 \$	2024 \$
3.2.1		Current			
		Trade receivables		17,228	31,662
		Research and development tax incentive rebate receivable	3.2.2	635,592	1,193,629
		Other receivables		377	33,593
				653,197	1,258,884
3.2.2		The Group continued its development program during the year ended 30 June 2025 resulting in a claim for research and development tax incentive which has been included as a receivable at year end.			
3.3		Other assets	Note	2025 \$	2024 \$
3.3.1		Current			
		Prepayments – Raw materials		5,096	28,680
				5,096	28,680
3.4		Trade and other payables	Note	2025 \$	2024 \$
3.4.1		Current			
		Unsecured			
		Trade payables		415,899	307,988
		Key management personnel related		1,676,858	1,979,688
		Sundry payables and accrued expenses		105,910	83,051
		Net Goods and Services Tax payable / (receivable)		14,216	(26,708)
				2,212,883	2,344,019

Notes to the preliminary final report

for the year ended 30 June 2025

Note 3 Financial assets and financial liabilities (cont.)

3.5 Borrowings	Note	2025 \$	2024 \$
3.5.1 Current			
R&D Rebate Advance Facility		433,256	716,780
Leases – motor vehicle		11,134	14,947
		444,390	731,727

Note 4 Non-financial assets and financial liabilities

4.1 Inventories	2025 \$	2024 \$
Finished goods	-	31,908
	-	31,908
4.2 Intangible assets	2025 \$	2024 \$
SE Formula™	9,859,296	9,859,296
Accumulated amortisation	(2,379,486)	(2,379,486)
Accumulated impairment	(7,479,810)	(7,479,810)
	-	-
Website development costs	55,410	55,410
Accumulated amortisation	(45,230)	(45,230)
Accumulated impairment	(10,180)	(10,180)
	-	-
Total intangibles	-	-

Note 5 Equity

5.1 Issued capital	Note	2025 No.	2024 No.	2025 \$	2024 \$
Fully paid ordinary shares		1,049,714,117	563,986,095	25,868,692	24,444,454
5.1.1 Ordinary shares		2025 No.	2024 No.	2025 \$	2024 \$
At the beginning of the year		563,986,095	543,986,095	24,444,454	24,244,454
Shares issued during the year:					
🌱 01.11.23 Placement		-	20,000,000	-	200,000
🌱 04.11.24 Debt for equity		166,666,667	-	500,000	-
🌱 04.12.24 Class A performance rights converted	5.3.1	100,000,000	-	380,000	-
🌱 07.03.25 Rights issue		171,230,552	-	513,692	-
🌱 13.03.25 Oversubscriptions		47,830,803	-	143,492	-
Share issue transaction costs		-	-	(112,946)	-
At end of the year		1,049,714,117	563,986,095	25,868,692	24,444,454

Notes to the preliminary final report

for the year ended 30 June 2025

Note 5 Equity (cont.)

5.1.2 Treasury shares

	2025 No.	2024 No.
At beginning of the year	25,500,000	25,500,000
At end of the year	25,500,000	25,500,000

a. Treasury shares are ordinary shares issued as collateral shares for nil consideration.

5.2 Options

Note

	2025 No.	2024 No.	2025 \$	2024 \$
Options on issue	410,412,553	191,351,198	335,827	335,827
5.2.1 Options movement during the year:	2025 No.	2024 No.	2025 \$	2024 \$
At the beginning of the year	191,351,198	197,351,198	335,827	335,827
🌱 01.11.23 Free attaching to Placement shares	-	20,000,000	-	-
🌱 15.03.24 Expiration of LDA options	-	(26,000,000)	-	-
🌱 07.03.25 Free attaching to Rights issue	171,230,552	-	-	-
🌱 13.03.25 Free attaching to Oversubscriptions	47,830,803	-	-	-
At end of the year	410,412,553	191,351,198	335,827	335,827
Comprising the following options:				
🌱 Unlisted				
○ \$0.05 options exp. 31.10.25	58,000,000	58,000,000		
○ \$0.01 options exp. 21.02.28	219,061,355	-		
🌱 Listed				
○ \$0.025 options exp. 31.05.26	133,351,198	133,351,198		
	410,412,553	191,351,198		

5.3 Performance rights

	2025 No.	2024 No.	2025 \$	2024 \$
Performance rights	62,000,000	62,000,000	-	-
5.3.1 Performance rights movement during the year:	2025 No.	2024 No.	2025 \$	2024 \$
At the beginning of the year	62,000,000	209,000,000	-	488,871
🌱 Amortisation of rights	-	-	-	235,226
🌱 Derecognition of rights not achieved (in profit and loss)	-	-	-	(511,584)
🌱 Cancellation of rights	(62,000,000)	-	-	-
🌱 Issue of Class A rights	100,000,000	-	380,000	-
🌱 Issue of Class B rights	62,000,000	-	-	-
🌱 Class A performance rights converted	(100,000,000)	-	(380,000)	-
🌱 Historically lapsed rights transferred within equity	-	(147,000,000)	-	(212,513)
At end of the year	62,000,000	62,000,000	-	-

5.1.1

Notes to the preliminary final report

for the year ended 30 June 2025

Note	5	Equity (cont.)			
5.4		Reserves	2025 \$	2024 \$	
5.4.1		Summary of share-based payment reserve			
		Options	5.2 335,827	335,827	
		Performance rights	5.3 -	-	
			335,827	335,827	
Note	6	Earnings per share (EPS)	2025 \$	2024 \$	
6.1		Reconciliation of loss to profit or loss			
		Loss for the year	(1,728,461)	(2,161,283)	
		Loss used in the calculation of basic and diluted EPS	(1,728,461)	(2,161,283)	
			2025 No.	2024 No.	
6.2		Weighted average number of ordinary shares outstanding during the year used in calculation of basic EPS	557,264,784	557,264,784	
		Weighted average number of dilutive equity instruments outstanding	N/A	N/A	
6.3		Weighted average number of ordinary shares outstanding during the year used in calculation of basic EPS	557,264,784	557,264,784	
6.4		Earnings per share	2025 ¢	2024 ¢	
		Basic EPS (cents per share)	(0.31)	(0.39)	
		Diluted EPS (cents per share)	N/A	N/A	
Note	7	Share-based payments	Note	2025 \$	2024 \$
7.1		Share-based payments:			
		Net recognised in profit and loss or (derecognised) as a contra expense		380,000	(276,358)
		Recognised in net assets (payables)		500,000	-
		Gross share-based payments		880,000	(276,358)

For personal use only



Skin Elements Limited (ASX:SKN)

1255A Hay Street West Perth, Western Australia 6005
Australia

P 08 6311 1900 F 08 6311 1999

www.skinelementslimited.com

info@skinelementslimited.com

www.sknlife.com.au